BOSTON, May 22, 2025 /PRNewswire/ -- Servier today announced that it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on May 30 – June 3 in Chicago. Presentations will span across a range of cancers including chondrosarcoma, cholangiocarcinoma and myelodysplastic syndrome, reinforcing Servier's commitment to the development of precision medicines for isocitrate dehydrogenase (IDH) mutated cancers. "As industry leaders in IDH-

Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancers Patient-reported outcomes from the Beamion LUNG-1 study in previously treated patients with HER2 (ERRB2)-mutant advanced non-small cell lung cancer (NSCLC) reported physical function and disease-related symptom improvement while being treated with zongertinib1 New data from a study of T-cell engager, obrixtamig, show encouraging findings in the treat

NEW YORK, May 22, 2025 /PRNewswire/ -- Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today announced additional results from its Phase 2 study (NCT05023486) evaluating NP-G2-044 in combination with SOC anti-PD-1 therapy in patients with advanced solid tumors resistant to prior anti-PD-1 therapy at the 2025 American Society of Clinical Oncology (ASCO)

ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focus on advanced or metastatic patients with BRCA-1 and/or BRCA-2-deficient breast cancer or MSI-H and/or dMMR solid tumors LEXINGTON, Mass., May 22, 2025 /PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, today announced that a Trial in Progress poster for its first-in-human, Phase 1/2 study of its first-in-cl

CHICAGO, May 22, 2025 /PRNewswire/ -- Cizzle Bio, Inc. announced today the online publication of a new study abstract in conjunction with the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, projecting that its proprietary CIZ1B biomarker blood test for early-stage lung cancer could save the U.S. Medicare program up to $518 million annually. Co-authored by healthcare economist Jennifer Hinkel, M.Sc., the study models how integrating CIZ1B into lung cancer screening for high-risk

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in me

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancer ZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster at ESMO Gynaecological Cancers Congress; trial enrollment

Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company’s Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizum

May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is propo

Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy Targeting Lupus Nephritis, Systemic Lupus Erythematosus and Multiple Sclerosis Phase 1, First-in-Human Investigator-Initiated Trial (IIT) ROCKVILLE, Md., May 22, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that data from its Phase 1 first-in-